NL-OMON39351已完成不适用
Early monitoring of trastuzumab +/- pertuzumab therapy with 18F-choline PET/CT in patients with advanced disease breastcancer. - Trastuzumab +/- pertuzumab PET/CT pilotstudy.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Her2/neu receptor positive breastcancer with new distant metastases, qualifying for initial regular therapy with trastuzumab, docetaxel and pertuzumab (facultatively)
- •At least 18 years old and
- •Mentally competent
排除标准
- •Younger than 18 years old
- •Mentally incompetent
研究者
相似试验
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
已完成
2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab TherapyHER2-Positive Metastatic Breast CancerJPRN-UMIN000012452Chiba Youth Breast Oncology Research Group (CYBORG)35
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30
进行中（未招募）
2 期
Extension study for HER2 amplified advanced solid tumors (JUPITER ES)JPRN-jRCTs031220444Ikeda Sadakatsu3
暂停
不适用
Phase II trial of pertuzumab and trastuzumab in combination with S-1 for patients with HER2-positive metastatic breast cancerBreast cancerJPRN-UMIN000024477Kurume University School of Medicine32